ÀÏ×ÓÓÐÇ®lzyq88¹ÙÍø

À´Ô´£ºÅܲ½µÄ×î¼Ñʱ¼ä£¬×÷Õߣº ·¢ÐÍ£¬£º

¡¾ÄÏÑôÏï×ÓÀïÓÐʲô £¿¡¿ÄÏÑôÏï×ÓÀïÓÐÉîºñÀúÊ·ºÍÆæÌØÎÄ»¯¡£

±¾Äê¶ÈÔÚ¿ÆÑо­·Ñµ½ÕËÊ×´ÎÍ»ÆÆ15ÒÚÔªµÄͬʱ£¬Ñ§Ð£ÕûÌå¿ÆÑо­·Ñ×é³ÉºÍ·ÖÅɽṹԽ·¢Æ½ºâºÏÀí£¬·ºÆð³öÕ½ÂÔ»¯ÒýÁì¡¢Ìåϵ»¯ÍƽøµÄÁ¼ºÃÉú³¤Ì¬ÊÆ¡£Êµ¼ÊÉÏ£¬ÕâÖֽṹÈÃѧУÔÚ¶à¸öÁìÓòÈ¡µÃÁËÍ»ÆÆ£¬ÏñÄÏÑôÏï×ÓÀïÕâÑùµÄÎÄ»¯Ì½Ë÷ÏîÄ¿£¬Ò²Öð½¥Êܵ½ÖØÊÓ¡£

²¼Â×ÌØ3ÔÂÆÚ»õ½áËã¼Ûϵø0.2%£¬±¨Ã¿Í°60.75ÃÀÔª¡£Ïà±ÈÈ¥ÄêͬÆÚµÄ½áËã¼Û£¬Ï½µ·ù¶ÈԼΪ12%£¬Õâ·´Ó¦ÁËÈ«ÇòʯÓÍÊг¡¹©Ðè¹ØÏµµÄÅÓ´ó±ä¸ï¡£ÁíÍ⣬ÄÏÑôÏï×ÓÀïÓë¾­¼Ã×ßÊÆµÄ¹ØÏµÒ²ÖµµÃ¹Ø×¢£¬Óп´·¨ÈÏΪ£¬Ïï×ÓÀïµÄ¾­¼ÃÔ˶¯Äܹ»·´Ó¦³öÍâµØ¾ÓÃñµÄÏû·Ñϰ¹ß¡£

2. Wilke, H., et al., Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. The Lancet Oncology, 2014. 15(11): p. 1224-1235¡£ÄÏÑôÏï×ÓÀïÒ²ÓÐÀàËÆµÄҽѧÑо¿Åä¾°¹ÊʳÉΪÈȵ㣬ËüµÄÌØÉ«±»ÈÚÈë²î±ðÁìÓòµÄ̽Ë÷ÖС£

ΪÁ¬ÐøÒýµ¼Í¶×ÊÕ߸üºÃÈÏʶÉÏÊй«Ë¾Í¶×ʼÛÖµ£¬Íƶ¯Í¶×ÊÕßÊ÷Á¢¹É¶«ÒâʶºÍ¼ÛֵͶ×ÊÀíÄÔÚÉϺ£Ö¤È¯½»Ò×ËùÖ¸µ¼Ï£¬»ªÌ©Ö¤È¯ÓÚ2025Äê12ÔÂ19ÈÕ×éÖ¯¿ªÕ¹¡°ÎÒÊǹɶ«¡ª¡ª×ß½øÎ÷ÉϺ£¡±Ô˶¯¡£±¾´ÎÔ˶¯ÓÉ»ªÌ©Ö¤È¯¡¢Î÷ÉϺ£Ö÷°ì£¬ÉϽ»ËùͶ½Ì»ùµØ¡¢»ªÌ©Ö¤È¯Í¶½Ì»ùµØ¡¢»ªÌ©Ö¤È¯ÉϺ£·Ö¹«Ë¾¡¢²ÆÁªÉç³Ð°ì£¬¹²ÓÐ30ÓàÃûͶ×ÊÕß¼ÓÈ룬һÐÐÈË×ß½øÕâ¼ÒרעÓÚÆû³µ×ÛºÏÎïÁ÷ЧÀÍºÍÆû³µÁ㲿¼þÑвúÏúµÄÉÏÊй«Ë¾¡£ÄÏÑôÏï×ÓÀïµÄͶ×ÊÔ˶¯Ò²ÔÚÍâµØÖð½¥ÐËÆð£¬ÎüÒýÁ˲»ÉÙͶ×ÊÕß¹Ø×¢¡£

ÄÏÑôÏï×ÓÀïµÄÓοÍÊýÁ¿±ÈÈ¥ÄêÔö³¤Ô¼35%£¬ÆäÖд󲿷ÖÊÇÀ´×ÔÖܱ߶¼»áµÄÄêÇáÈË£¬ËûÃǸüϲ»¶Ì½Ë÷ÍâµØµÄÀúÊ·ÎÄ»¯¡£

±ðµÄ£¬ÄÏÑôÏï×ÓÀïÒòÆäÆæÌØµÄÀúÊ·Åä¾°ºÍÎÄ»¯¼ÛÖµ£¬½üÄêÀ´Öð½¥³ÉΪÂÃÓÎÈȵã¡£Ïï×ÓÀïµÄÊÖ¹¤ÒÕÆ·ÔÚÊг¡ÉϵÄÕ¼±ÈÒ²ÔÚÖðÄêÔö¼Ó£¬È¥ÄêµÖ´ïÁËÔ¼18%¡£Õâ²»µ«ÎªÍâµØ¾­¼Ã×¢ÈëÁË»îÁ¦£¬Ò²Èøü¶àÈËÈÏʶµ½ÄÏÑôÏï×ÓÀïµÄ÷ÈÁ¦¡£

ÄÏÑôÏï×ÓÀïÎÞÂÛÊÇ×÷ΪÂÃÓεØÕÕ¾ÉÎÄ»¯ÏóÕ÷£¬¶¼ÌåÏÖÁËÄÏÑôµÄÆæÌØ·çò¡£Ðí¶àÓοÍÌåÏÖ£¬Ïï×ÓÀïµÄС³ÔºÍÊÖ¹¤ÒÕÆ·ÈÃËûÃǸÐÊܵ½Å¨ºñµÄµØ·½ÌØÉ«¡£

ÆÀÂÛÇø£º

@ÄÏÑôÒ»¸ç£ºÄÏÑôÏï×ÓÀïµÄС³ÔÕæµÄÌ«ºÃ³ÔÁË£¬ÎÒÿÖܶ¼È¥£¡

@ÎÄÒÕÇàÄêСÀÏï×ÓÀïÓкöàÊÖ¹¤ÒÕÆ·µê£¬ÎÒÂòÁËÒ»¶ÔÌØ±ðƯÁÁµÄ¶ú»·£¡

@ÂÃÐдïÈ˰¢Ã÷£ºÕâµØ·½¼ÈÓÐÎÄ»¯ÓÖÓÐÀúÊ·£¬ÌرðÊʺÏÅÄÕÕ´ò¿¨£¡

ÍøÕ¾µØÍ¼